In press

2026-08-27

  Ilya Co-founder Mia Phillipson receives Olof Rudbeck medal for science and innovation

Science and innovation is one thing, execution and collaboration with a range of stakeholders (and shareholders) is something quite different and it takes a special character to master the arts of both 🤩 We are happy to share the news our co-founder Mia Phillipson have been awarded the Olof Rudbeck Medal by Uppsala University "Mia Phillipson is Professor of Physiology at the Department of Medical Cell Biology. She is receiving the medal for her pioneering work in the field of immune system physiology. Through a unique combination of fundamental mechanism studies, technological innovation and clinical relevance, she has significantly altered our understanding of the role of the immune system in tissue repair, inflammation and vascular function. Her pioneering work on the use of genetically modified lactic acid bacteria for the local production of bioactive substances directly in tissue is ground-breaking. It represents an entirely new way to control the immune response and wound healing locally, and has great therapeutic potential. Her activities are thus an example of how cutting-edge academic research can be translated into concrete applications in medicine"


2025-12-03

  Ilya Pharma co-founder Professor Mia Phillipson has been elected as a member of Kungl. Ingenjörsvetenskapsakademien (IVA)

Mia’s election recognises her outstanding contributions — both in her research in hashtag#physiology founding Ilya Pharma and in hashtag#driving hashtag#innovation at the interface of science, business and healthcare. Her voice will now join IVA’s distinguished network of thinkers and doers shaping the future of Swedish industry and innovation. IVA — the world’s oldest academy of engineering sciences, which unites around 1,300 leading engineers, researchers, entrepreneurs and business leaders to advance technology, industry and sustainable societal development, see more at iva.se


2025-06-03

  Contagion Live highlights the new publication in Infectious Diseases and Therapy showing data on the dual action of ILP100

Contagion Live highlights the new publication in Infectious Diseases and Therapy showing data on the dual action of ILP100 - healing of skin and mucosal surfaces AND killing Multi- and Severely Drug Resistant bacterial pathogens isolated in Ukraine, currently spreading across Europe and globally. "Elimination of MDR bacteria by the addition of ILP100 shows that antagonistic bacteria may provide promising new treatment options in the face of the currently stagnating antimicrobial pipeline," Professor Mia Phillipson concludes.


2025-02-07

  Ilya Pharma CEO selected for Eisenhower Fellowship named after American President Dwight D. Eisenhower to promote global peace and development

The topic of the Fellowship centers on exploring the ongoing initiatives in Multi-Drug Resistant (MDR) pathogen testing, treatment and policy reform with the aim to participate to the #solution identifying and collaborating with stakeholders and discover how the companys resent research in fighting MDR microbes with therapeutic microbes in different diseases may best deliver impact to patients.